Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Monday. The firm issued a hold rating on the medical research company’s stock.

A number of other equities analysts also recently weighed in on CTSO. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Friday, January 3rd. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Cytosorbents has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.05 on Monday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company’s fifty day moving average price is $0.92 and its 200-day moving average price is $1.03. The stock has a market cap of $57.41 million, a PE ratio of -2.92 and a beta of 0.58. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC raised its stake in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new position in shares of Cytosorbents during the third quarter valued at $51,000. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.